Patents Examined by David L. Fitzgerald
  • Patent number: 6436391
    Abstract: The use of IFN-&agr; subtypes as vaccine adjuvants is disclosed, together with vaccine compositions comprising them. Methods of vaccinating a subject comprising co-administration of IFN-&agr; subtypes are also provided.
    Type: Grant
    Filed: January 31, 1997
    Date of Patent: August 20, 2002
    Assignee: Imperial College of Science, Technology & Medicine
    Inventors: Graham Russell Foster, Howard Christopher Thomas
  • Patent number: 6323006
    Abstract: The invention provides a new human interferon (IFN)-&bgr; variant cloned from an amniotic cell library, a cDNA encoding it, and processes for its production and purification. The variant, termed interferon beta-cis, differs from previously known hIFN-&bgr; isoforms by the substitution of a Cys residue for the Tyr present at position 60. Recombinant IFN beta-cis exhibits antiviral activity characteristic of IFN-&bgr;.
    Type: Grant
    Filed: July 13, 1999
    Date of Patent: November 27, 2001
    Assignee: Universidade Federal de Minas Gerais
    Inventors: Paulo Cesar Peregrino Ferreira, Erna Geessien Kroon, Romain Rolland Golgher, Claudio Antonio Bonjardim, Alex Fiorini De Carvalho
  • Patent number: 6258944
    Abstract: The ob receptor has numerous isoforms resulting from alternative splicaing; three novel isoforms, designated c′, f, and g are disclosed. The nucleic acids encoding these isoforms are taught. Also part of the invention are vectors containing the nucleic acid encoding the receptors, host cells transformed with these genes, and assays which use the genes or protein isoforms.
    Type: Grant
    Filed: May 6, 1997
    Date of Patent: July 10, 2001
    Assignee: Merck & Co., Inc.
    Inventors: C. Thomas Caskey, Patricia Hey, John W. Hess, Michael Sean Phillips
  • Patent number: 6255459
    Abstract: The invention provides antibodies directed against a G protein-activated, inward rectifying KGA potassium channel polypeptide.
    Type: Grant
    Filed: March 16, 1998
    Date of Patent: July 3, 2001
    Assignee: California Institute of Technology
    Inventors: Henry A. Lester, Nathan Dascal, Nancy F. Lim, Wolfgang Schreibmayer, Norman Davidson
  • Patent number: 6238889
    Abstract: The invention relates to nucleotide sequences encoding human interleukin-3 (hIL-3) as well as recombinant DNAs, expression cassettes, transformed host cells, and recombinant expression methods comprising such sequences. Additionally, the invention describes proteins having hIL-3 activity, as purified, recombinantly produced, or fusion protein forms of hIL-3, as well as methods of using such proteins to produce antibodies capable of immunospecific reaction with hIL-3.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 29, 2001
    Assignee: DSM N.V.
    Inventors: Lambertus Christian Johannes Dorssers, Gerard Wagemaker, Yvonne Johanna Vos, Robert Willem Van Leen
  • Patent number: 6214584
    Abstract: A polypeptide which has a molecular weight of 18,500±3,000 daltons on SDS-PAGE and a pI of 4.9±1.0 on chromatofocusing. The polypeptide strongly induces the IFN-&ggr; production by immunocompetent cells with only a small amount, and does not cause serious side effects even when administered to human in a relatively-high dose. It can be used to treat and/or prevent malignant tumors, viral diseases, bacterial infectious diseases, and immune diseases.
    Type: Grant
    Filed: April 8, 1997
    Date of Patent: April 10, 2001
    Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
    Inventors: Shimpei Ushio, Kakuji Torigoe, Tadao Tanimoto, Haruki Okamura, Masashi Kurimoto
  • Patent number: 6207814
    Abstract: The invention relates to two members of the receptor family referred to as activin-like kinases. These two members are referred to as ALK-3 and ALK-6. The proteins have activin/TGF-&bgr; type I receptor functionality, and may have a serine/threonine kinase domain, a DFKSRN or DLKSKN sequence in subdomain V1B, and/or a GTKRYM sequence in subdomain VIII.
    Type: Grant
    Filed: August 24, 1999
    Date of Patent: March 27, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Kohei Miyazono, Peter ten Dijke, Petra Franzen, Hidetoshi Yamashita, Carl-Henrik Heldin
  • Patent number: 6204022
    Abstract: The invention describes a method of reducing the cytotoxicity of interferon-alpha by making defined amino acid substitutions in the N-terminal portion of the polypeptide sequence. Also described are human interferon-alpha analogs with low cytotoxicity, and therapeutic applications of the low toxicity interferon-alpha analogs.
    Type: Grant
    Filed: October 20, 1997
    Date of Patent: March 20, 2001
    Assignee: Pepgen Corporation and University of Florida
    Inventors: Howard M. Johnson, Carol H. Pontzer, Prem S. Subramaniam, Lorelie H. Villarete, Jackeline Campos
  • Patent number: 6201105
    Abstract: Tumor necrosis factor receptor proteins, DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: January 20, 1999
    Date of Patent: March 13, 2001
    Inventors: Craig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann
  • Patent number: 6200780
    Abstract: The invention concerns a novel human interferon-&egr;, originally designated PRO655, and its variants and derivatives. The novel interferon is related to but distinct from members of the IFN-&agr; family and from IFNs-&bgr; and -&ggr;. Nucleic acid encoding the novel polypeptide, and methods and means for their recombinant production are also included.
    Type: Grant
    Filed: December 7, 1998
    Date of Patent: March 13, 2001
    Assignee: Genentech, Inc.
    Inventors: Jian Chen, Paul J. Godowski, William I. Wood, Dong-Xiao Zhang
  • Patent number: 6200559
    Abstract: The invention provides methods of indirectly measuring the level of type I interferons in vivo utilizing antibodies directed against MxA and/or MxB. The methods find application in conjunction with therapies directed to raising or lowering the levels of interferons in patients. Also provided are new monoclonal antibodies that recognize specific human Mx protein(s).
    Type: Grant
    Filed: October 18, 1999
    Date of Patent: March 13, 2001
    Inventor: Peter von Wussow
  • Patent number: 6197541
    Abstract: The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the detection of thrombin and for the evaluation of candidate thrombin agonists and antagonists. Further, the elucidation of the structure of the thrombin receptor permits the design of agonist and antagonist compounds which are useful diagnostically and therapeutically. The availability of the thrombin receptor also permits production of antibodies specifically immunoreactive with the receptor per se or with specific regions thereof which are also useful diagnostically or therapeutically.
    Type: Grant
    Filed: February 17, 1993
    Date of Patent: March 6, 2001
    Assignees: COR Therapeutics, Inc., Regents of the University of California
    Inventor: Shaun R. Coughlin
  • Patent number: 6187304
    Abstract: The invention concerns the treatment of cardiac hypertrophy by interferon-gamma (IFN-&ggr;). Cardiac hypertrophy may result from a variety of diverse pathologic conditions, including myocardial infarction, hypertension, hypertrophic cardiomyopathy, and valvular regurgitation. The treatment extends to all stages of the progression of cardiac hypertrophy, with or without structural damage of the heart muscle, regardless of the underlying cardiac disorder.
    Type: Grant
    Filed: March 19, 1999
    Date of Patent: February 13, 2001
    Assignee: Genentech, Inc.
    Inventors: Hongkui Jin, Hsienwie Lu, Nicholas F. Paoni, Renhui Yang
  • Patent number: 6187564
    Abstract: Provided are nucleic acids encoding multimeric erythropoietin (EPO) proteins and having modifications in the 5′ and 3′ noncoding sequences relative to the corresponding sequences in native EPO DNA. The invention also relates to the use of such nucleic acids to produce multimeric EPO proteins, which may have altered activity as compared to EPO multimers expressed from nucleic acids having native 5′ and 3′ sequences.
    Type: Grant
    Filed: February 3, 1998
    Date of Patent: February 13, 2001
    Assignee: Beth Israel Deaconess Medical Center
    Inventor: Arthur J. Sytkowski
  • Patent number: 6180773
    Abstract: The CC type chemokines belong to a family of polypeptides which have proven to be mediators of immune reactions, and they have recently attracted attention due to their antiviral activity with respect to HIV. The cloning and molecular characterization of a human tandem gene is disclosed which contains the closely linked coding regions for two new CC type chemokines the sequences of which are highly homologous with that of MIP-1&agr;. The transcription of the tandem gene leads to a bicistronic mature transcript which contains the non-overlapping open reading frames for the recently described factor HCC-1 and an as yet unknown CC type chemokine, designated as CC-2. Moreover, alternative splicing of the primary transcript yields at least one additional CC type chemokine, cytokine CC-3. Two functional promoter regions were identified within the tandem gene.
    Type: Grant
    Filed: December 30, 1998
    Date of Patent: January 30, 2001
    Inventors: Wolf-Georg Forssmann, Andreas Pardigol, Hans-J{umlaut over (u)}rgen M{umlaut over (a)}gert, Peter Schulz-Knappe
  • Patent number: 6177543
    Abstract: Biologically active lymphotoxin polypeptides are synthesized in recombinant cell culture. Novel nucleic acid and vectors incorporating same are provided. The compositions and processes herein enable the economical preparation of compositions containing uniform lymphotoxin polypeptides and variant lymphotoxins having amino acid sequences that differ from those found in nature. The lymphotoxins are purified to a specific activity of 2-10×107 units/mg of protein by purification using a novel immobilized, lymphotoxin-neutralizing monoclonal antibody.
    Type: Grant
    Filed: March 19, 1998
    Date of Patent: January 23, 2001
    Assignee: Genentech, Inc.
    Inventors: Bharat B. Aggarwal, Patrick W. Gray, Glenn E. Nedwin
  • Patent number: 6174996
    Abstract: The invention provides fusion proteins comprising an N-terminal region derived from an interferon-tau (IFN-&tgr;) polypeptide and a C-terminal region derived from another type I interferon polypeptide, such as IFN-&agr; or IFN-&bgr;. The fusion proteins exhibit reduced cytotoxicity as compared to the corresponding unmodified type I interferons.
    Type: Grant
    Filed: March 20, 1998
    Date of Patent: January 16, 2001
    Assignee: University of Florida
    Inventors: Howard Marcellus Johnson, Carol Hanlon Pontzer
  • Patent number: 6169070
    Abstract: The translation product of the growth arrest-specific gene 6 (gas6) has been identified as an activator of the Mer receptor protein tyrosine kinase. The invention accordingly provides methods of activating Mer receptor in cells expressing it by exposing them to exogenous gas6 polypeptides. Also provided are methods of enhancing the growth, differentiation, or survival of such cells using gas6 polypeptides.
    Type: Grant
    Filed: April 17, 1996
    Date of Patent: January 2, 2001
    Assignee: Genentech, Inc.
    Inventors: Jian Chen, R. Glenn Hammonds, Paul J. Godowski, Melanie R. Mark, Jennie P. Mather, Ronghao Li
  • Patent number: 6169068
    Abstract: A method is disclosed for treating diseases or disorders involving complement by pulmonary administration of complement inhibitory proteins such as soluble complement receptor type 1 (sCR1). The present invention relates to the direct treatment of certain complement related disorders by administering complement inhibitory proteins via the pulmonary route, in particular, by direct delivery to the lungs by aerosolization of a complement inhibitory protein and subsequent inhalation.
    Type: Grant
    Filed: August 11, 1995
    Date of Patent: January 2, 2001
    Assignees: Avant Immunotherpeutics, Inc., Regents of the University of Minnesota
    Inventors: James L. Levin, Jean F. Regal, Carol A. Toth
  • Patent number: 6162896
    Abstract: In accordance with the present invention, there are provided novel receptor proteins characterized by having the following domains, reading from the N-terminal end of said protein:an extracellular, ligand-binding domain,a hydrophobic, trans-membrane domain, andan intracellular, receptor domain having serine kinase-like activity.The invention receptors optionally further comprise a second hydrophobic domain at the amino terminus thereof. The invention receptor proteins are further characterized by having sufficient binding affinity for at least one member of the activin/TGF-.beta. superfamily of polypeptide growth factors such that concentrations of .ltoreq.10 nM of said polypeptide growth factor occupy .gtoreq.50% of the binding sites of said receptor protein. A presently preferred member of the invention superfamily of receptors binds specifically to activins, in preference to inhibins, transforming growth factory-.beta., and other non-activin-like proteins.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 19, 2000
    Assignee: The Salk Institute for Biological Studies
    Inventors: Lawrence W. Mathews, Wylie W. Vale, Jr., Kunihiro Tsuchida